S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Biden To Unleash "Choke Point" Operation On America? (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Fed's Shocking New Plan to Control Your Money (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Biden To Unleash "Choke Point" Operation On America? (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Fed's Shocking New Plan to Control Your Money (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Biden To Unleash "Choke Point" Operation On America? (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Fed's Shocking New Plan to Control Your Money (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Biden To Unleash "Choke Point" Operation On America? (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Fed's Shocking New Plan to Control Your Money (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film

Adial Pharmaceuticals - ADIL Stock Forecast, Price & News

$0.35
-0.03 (-7.85%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.35
$0.40
50-Day Range
$0.31
$0.56
52-Week Range
$0.20
$2.27
Volume
167,638 shs
Average Volume
1.65 million shs
Market Capitalization
$10.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Adial Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
751.8% Upside
$3.00 Price Target
Short Interest
Healthy
1.34% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.69mentions of Adial Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.56) to ($0.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

617th out of 1,005 stocks

Pharmaceutical Preparations Industry

293rd out of 486 stocks


ADIL stock logo

About Adial Pharmaceuticals (NASDAQ:ADIL) Stock

Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.

Receive ADIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADIL Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Adial Pharma Surges 80% On Update Of AD04
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Adial Pharmaceuticals GAAP EPS of -$0.12 beats by $0.06
ADIL Adial Pharmaceuticals, Inc.
Adial Clinical Trial: A Fluff Or A Win?
See More Headlines
Receive ADIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADIL Company Calendar

Last Earnings
8/11/2021
Today
3/26/2023
Next Earnings (Estimated)
3/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADIL
Fax
N/A
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+751.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-19,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.17 per share

Miscellaneous

Free Float
22,466,000
Market Cap
$10.04 million
Optionable
Not Optionable
Beta
0.99

Key Executives

  • Cary J. Claiborne
    President, Chief Executive Officer & Director
  • Joseph Truluck
    Chief Financial Officer, Secretary & Treasurer
  • Bankole A. JohnsonBankole A. Johnson
    Chief Medical Officer
  • Julien Dimastromatteo
    Vice President-Research
  • Alex Lugovoy
    Chief Business Officer













ADIL Stock - Frequently Asked Questions

Should I buy or sell Adial Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADIL shares.
View ADIL analyst ratings
or view top-rated stocks.

What is Adial Pharmaceuticals' stock price forecast for 2023?

2 equities research analysts have issued 12-month price targets for Adial Pharmaceuticals' shares. Their ADIL share price forecasts range from $3.00 to $3.00. On average, they anticipate the company's share price to reach $3.00 in the next year. This suggests a possible upside of 751.8% from the stock's current price.
View analysts price targets for ADIL
or view top-rated stocks among Wall Street analysts.

How have ADIL shares performed in 2023?

Adial Pharmaceuticals' stock was trading at $0.2150 at the beginning of the year. Since then, ADIL stock has increased by 63.8% and is now trading at $0.3522.
View the best growth stocks for 2023 here
.

When is Adial Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our ADIL earnings forecast
.

How were Adial Pharmaceuticals' earnings last quarter?

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) released its earnings results on Wednesday, August, 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.05.

What other stocks do shareholders of Adial Pharmaceuticals own?
When did Adial Pharmaceuticals IPO?

(ADIL) raised $8 million in an initial public offering (IPO) on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager.

What is Adial Pharmaceuticals' stock symbol?

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

Who are Adial Pharmaceuticals' major shareholders?

Adial Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.97%). Insiders that own company stock include Bankole A Johnson, James W Jr Newman and William B Stilley III.
View institutional ownership trends
.

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adial Pharmaceuticals' stock price today?

One share of ADIL stock can currently be purchased for approximately $0.35.

How much money does Adial Pharmaceuticals make?

Adial Pharmaceuticals (NASDAQ:ADIL) has a market capitalization of $10.04 million. The company earns $-19,420,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

How can I contact Adial Pharmaceuticals?

Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The official website for the company is www.adialpharma.com. The company can be reached via phone at (434) 422-9800 or via email at investor_relations@haynesintl.com.

This page (NASDAQ:ADIL) was last updated on 3/26/2023 by MarketBeat.com Staff